Universal DX secures €20 million loan from EIB to advance early cancer detection

Seville-based Universal DX, a HealthTech start-up, has actually protected a EUR20 million finance from the European Financial Investment Financial Institution (EIB) to sustain the advancement and commercialisation of its blood-based fluid biopsy remedies.

The financing will certainly drive the development of Signal-C ®, its most sophisticated intestines cancer cells testing item, along with the advancement of brand-new remedies for liver and lung cancer cells discovery (Signal-Li and Signal-Lu, specifically).

Juan Martínez Barea, Creator and head of state of Universal DX, shared his interest for the collaboration: ” Our goal is to produce a future where cancer cells is treatable. With the transformative power of our modern technology, we are taking strong actions to transform this vision right into truth. We are deeply influenced by the assistance of the EIB, which will certainly allow us to add to the European Strategy to combat Cancer cells and to bring our innovative blood examinations for very early cancer cells discovery to both European and united state markets.”

Established In 2012, Universal DX is introducing AI-powered computational biology for very early cancer cells discovery. Its system integrates Next-Generation Sequencing (NGS) with exclusive biomarkers and progressed artificial intelligence formulas to determine very early cancer cells signals with high precision.

The EIB’s financial backing comes with a turning point for the start-up as it prepares to broaden right into global markets. A crucial following action is a professional test in the USA, going for FDA authorization, which would certainly help with compensation and combination right into the American medical care system.

“ We are thrilled to sign up with pressures with Universal DX to progress the battle versus cancer cells and even more particularly the very early discovery of the ailment to enhance survival price. This funding contract is another instance of exactly how the EIB is aiding ingenious European start-ups establishing innovation clinical remedies and sustaining the European MedTech market,” stated EIB Supervisor of Equity, Development Funding and Task Money Alessandro Izzo

The financial investment is backed by the InvestEU program, which intends to mobilise over EUR372 billion in tactical financial investments in between 2021 and 2027. The task adds to Europe’s Pounding Cancer cells Strategy and the EIB Team tactical top priority of increasing digitalisation and technical technology.

This contract aims to not just speed up Universal DX’s development yet likewise reinforce Europe’s competition in the biotechnology field. By integrating tactical financial investment with advanced modern technology, the start-up is placing itself as a principal in making very early cancer cells discovery much more easily accessible globally.

The article Universal DX secures €20 million loan from EIB to advance early cancer detection showed up initially on EU-Startups.